Strasser-Weippl K, et al. - Researchers investigated whether celecoxib and low-dose aspirin decreases the risk of breast cancer recurrence in postmenopausal hormone receptor–positive breast cancer patients who were randomly assigned (2 × 2) to adjuvant exemestane or anastrozole, and celecoxib or placebo in the Canadian Cancer Trials Group MA.27. They assessed the impacts of celecoxib and low-dose aspirin on event-free survival (EFS), distant disease–free survival (DDFS), and overall survival. All statistical tests were two-sided. In multivariable analysis, DDFS and EFS remained unaltered following random assignment to short-term (≤ 18 months) celecoxib as well as use of low-dose aspirin. The observed increase in “all-cause” mortality induced by low-dose aspirin was presumably attributed to higher preexisting cardiovascular risks.